

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): March 5, 2014

**Bacterin International Holdings, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

001-34951

(Commission File Number)

20-5313323

(IRS Employer Identification No.)

600 Cruiser Lane  
Belgrade, Montana

(Address of Principal Executive Offices)

59714

(Zip Code)

(406) 388-0480

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

The Company has issued a press release entitled “Bacterin to Present at the Canaccord Genuity Musculoskeletal Conference - UPDATE” which is attached as Exhibit 99.1 and incorporated herein.

The information in this Item 7.01 and the document attached as Exhibit 99.1 are being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), nor otherwise subject to the liabilities of that section, nor incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

<u>Exhibit No</u>	<u>Description</u>
99.1	Press Release of Bacterin International Holdings, Inc. dated March 5, 2014 entitled “Bacterin to Present at the Canaccord Genuity Musculoskeletal Conference - UPDATE”

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 5, 2014

**BACTERIN INTERNATIONAL HOLDINGS, INC.**

By: /s/ John Gandolfo

Name: John Gandolfo

Title: CFO

---

## EXHIBIT INDEX

99.1 Press Release of Bacterin International Holdings, Inc. dated March 5, 2014 entitled "Bacterin to Present at the Canaccord Genuity Musculoskeletal Conference - UPDATE"

---



## **Bacterin to Present at the Canaccord Genuity Musculoskeletal Conference - UPDATE**

**BELGRADE, MT, March 5, 2014** -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone grafts and coatings for medical applications, today announced that its CEO, Dan Goldberger, will present at the Canaccord Genuity Musculoskeletal Conference, to be held March 11, 2014 at the Sheraton New Orleans. Bacterin's presentation will take place Tuesday, March 11, 2014 at 2:50 PM CST [TIME UPDATED FROM PREVIOUS RELEASE].

A live broadcast of the conference presentation will be available. To access the broadcast, go to the "Investor Info" section of the Company's website at [www.bacterin.com](http://www.bacterin.com). A replay of the conference presentation will also be available.

### **About Bacterin International Holdings**

Bacterin International Holdings, Inc. (NYSE MKT: BONE) develops, manufactures and markets biologics products to domestic and international markets. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops, employs, and licenses coatings for various medical device applications. For further information, please visit [www.bacterin.com](http://www.bacterin.com).

### **Contact:**

COCKRELL GROUP

877.889.1972

[investorrelations@thecockrellgroup.com](mailto:investorrelations@thecockrellgroup.com)

[cockrellgroup.com](http://cockrellgroup.com)

---